
Stefania Crucitta
@stefaniacrucit1
PhD, Pharma & Oncology research
ID: 1180549043891687424
05-10-2019 18:23:30
16 Tweet
19 Followers
116 Following


#ESMO19: David Olmos reports on PROfound - Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant #prostatecancer (mCRPC) with homologous recombination repair (HRR) gene alterations #pcsm youtube.com/watch?v=n73eFQ…

Immunotherapy options for 1L non-oncogene-addicted non-small cell lung cancer IASLC Dr. Antonio Calles 🫁🚭 Christian Rolfo OncoAlert #lungcancer #LungCancerAwarenessMonth


#OncoAlert TIM3 comes of age as an inhibitory receptor | Nature Rev Immunol TIM3, a marker of exhaustion. TIM3 is co-expressed and co-regulated on dysfunctional or ‘exhausted’ T cells in chronic viral infections and #cancer #ImmunoOnc nature.com/articles/s4157…





#Circulating #biomarkers of response to #immunotherapy in cancer treatment - Check out our new editorial on @PGSjournal! Alfredo Addeo MD Stefania Crucitta Ron van Schaik International Society of Liquid Biopsy doi.org/10.2217/pgs-20…


#PI3K confers primary #resistance to #CDK4/6 inhibitors. Should we reconsider treatment sequence in #PI3K mut #mBC pts? Find it out in our last published paper!💊🧬sciencedirect.com/science/articl… International Society of Liquid Biopsy Federico Cucchiara Stefania Crucitta @ghilli_m @Romano_Danesi SIF

#Pharmacology means: how the pharmacological profile of drugs influences mechanisms of #resistance in #cancer. Find it how and many thanks to all the coauthors! Joaquin Mateo Ron van Schaik Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Ilaria Attili, MD Stefania Crucitta Federico Cucchiara sciencedirect.com/science/articl…


